TriangleNCT02541604 · CITED IN SOURCE DOCUMENTS
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE1, PHASE2
- Status at capture
- TERMINATED
- Registry last update
- 2020-02-25
This early phase, multicenter, open-label, single-arm study evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of atezolizumab in pediatric and young adult participants with solid tumors for which prior treatment was proven to be ineffective.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Participants With Solid Tumors
Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) in Participants With Neuroblastoma
Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Response Assessment in Neuro-Oncology (RANO) Criteria in Participants With Atypical Teratoid Rhabdoid Tumor (ATRT)
Percentage of Participants With Clinical Benefit as Determined by the Investigator According to RECIST v1.1 Criteria in Participants With Osteosarcoma
Progression-Free Survival (PFS) as Determined by the Investigator Using RECIST v1.1 in Participants With Solid Tumors
PFS as Determined by the Investigator Using mINRC in Participants With Neuroblastoma
PFS as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
PFS as Determined by the Investigator Using RANO Criteria in Participants With ATRT
Percentage of Participants Adverse Events, Serious Adverse Events and Adverse Events of Special Interest
Maximum Serum Concentration (Cmax) of Atezolizumab
Minimum Serum Concentration (Cmin) of Atezolizumab
Atezolizumab Serum Concentration at Washout
Area Under the Concentration-Time Curve (AUC) of Atezolizumab
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 Criteria in Participants With Solid Tumors
DOR as Determined by the Investigator Using mINRC in Participants With Neuroblastoma
DOR as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
DOR as Determined by the Investigator Using RANO Criteria in Participants With ATRT
Overall Survival (OS)
Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Immune-Modified RECIST v1.1 for Participants With Other Solid Tumors
Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Immune-Related Response Criteria (irRC) for Participants With Neuroblastoma
Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using irRC for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
PFS as Determined by the Investigator Using Immune-Modified RECIST v1.1 for Participants With Other Solid Tumors
PFS as Determined by the Investigator Using irRC for Participants With Neuroblastoma
PFS as Determined by the Investigator Using irRC for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
DOR as Determined by the Investigator Using Immune-Modified RECIST v1.1 for Participants With Other Solid Tumors
DOR as Determined by the Investigator Using irRC for Participants With Neuroblastoma
DOR as Determined by the Investigator Using irRC for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Optimal Dose of Atezolizumab in Pediatric Adult Participants
Optimal Dose of Atezolizumab in Young Adult Participants
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Pediatric solid tumor (including Hodgkin's and Non-Hodgkin's lymphoma), for which prior treatment had proven to be ineffective (that is, relapsed or refractory) or intolerable * Disease that is measurable as defined by RECIST v1.1, mINRC, Revised Response Criteria for Malignant Lymphoma, RANO criteria (as appropriate) or evaluable by nuclear medicine techniques, immunocytochemistry techniques, tumor markers, or other reliable measures * Archival tumor tissue block or 15 freshly cut, unstained, serial slides available for submission, or willingness to undergo a core or excisional biopsy prior to enrollment (fine-needle aspiration, brush biopsy, and lavage samples are not acceptable). Participants with fewer than 15 slides available may be eligible for study entry following discussion with Medical Monitor * Lansky Performance Status (participants less than \[\<\] 16 years old) or Karnofsky Performance Status (participants greater than or equal to \[\>=\] 16 years old) \>=50 * Life expectancy \>=3 months, in the investigator's judgment * Adequate hematologic and end organ function, confirmed by laboratory results obtained within 28 days prior to initiation of study drug Exclusion Criteria: * Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases, except ATRT * Treatment with high-dose chemotherapy and hematopoietic stem-cell rescue within 3 months prior to initiation of study drug * Prior allogeneic hematopoietic stem-cell transplantation or prior solid-organ transplantation * Treatment with chemotherapy (other than high-dose chemotherapy as described above) or differentiation therapy (such as retinoic acid) or immunotherapy (such as anti-GD2 antibody treatment) within 3 weeks prior to initiation of study drug or, if treatment included nitrosoureas, within 6 weeks prior to initiation of study drug * Treatment with thoracic or mediastinal radiotherapy within 3 weeks prior to initiation of study drug * Treatment with hormonal therapy (except hormone replacement therapy or oral contraceptives) or biologic therapy within 4 weeks or 5 half-lives, whichever is shorter, prior to initiation of study drug. This requirement may be waived at the investigator's request if the participant has recovered from therapeutic toxicity to the degree specified in the protocol, with approval of the Medical Monitor * Treatment with a long-acting hematopoietic growth factor within 2 weeks prior to initiation of study drug or a short-acting hematopoietic growth factor within 1 week prior to initiation of study drug * Treatment with investigational therapy (with the exception of cancer therapies as described above) within 4 weeks prior to initiation of study drug * Treatment with a live vaccine or a live, attenuated vaccine (e.g., nasal spray of live attenuated influenza vaccine or FluMist®) within 4 weeks prior to initiation of study drug or anticipation that such treatment will be required during the study or within 5 months after the final dose of study drug * Treatment with herbal cancer therapy within 1 week prior to initiation of study drug * Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4), anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibodies * Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin 2 \[IL-2\]) within 6 weeks or five drug elimination half-lives prior to Day 1 of Cycle 1, whichever is longer * Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \[TNF\] agents) at the time of initiation of study drug, or anticipated requirement for systemic immunosuppressive medications during the study * Current treatment with therapeutic anticoagulants * Any non-hematologic toxicity (excluding alopecia) from prior treatment that has not resolved to Grade less than or equal to (\<=) 1 (per National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 4.0) at screening * Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
- healthy Volunteers
- false
- maximum Age
- 30 Years
- sex
- ALL
- std Ages
- CHILD
- ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams \[mg\]) on Day 1 of each 21-day cycle.
- intervention Names
- Drug: Atezolizumab
- label
- Atezolizumab
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Atezolizumab
- description
- Atezolizumab was administered as IV infusion (maximum 1200 mg) on Day 1 of each 21-day cycle.
- name
- Atezolizumab
- other Names
- RO5541267; MPDL3280A; Tecentriq
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 87
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Note: In Cohort 5, the response was observed in a rhabdoid tumor. Participant was erroneously enrolled in the Non-rhabdomyosarcoma soft tissue sarcoma cohort.
- measure
- Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Participants With Solid Tumors
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) in Participants With Neuroblastoma
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Response Assessment in Neuro-Oncology (RANO) Criteria in Participants With Atypical Teratoid Rhabdoid Tumor (ATRT)
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- Percentage of Participants With Clinical Benefit as Determined by the Investigator According to RECIST v1.1 Criteria in Participants With Osteosarcoma
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- Progression-Free Survival (PFS) as Determined by the Investigator Using RECIST v1.1 in Participants With Solid Tumors
- time Frame
- Baseline until first documented occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- PFS as Determined by the Investigator Using mINRC in Participants With Neuroblastoma
- time Frame
- Baseline until first documented occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- PFS as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
- time Frame
- Baseline until first documented occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- PFS as Determined by the Investigator Using RANO Criteria in Participants With ATRT
- time Frame
- Baseline until first documented occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- Percentage of Participants Adverse Events, Serious Adverse Events and Adverse Events of Special Interest
- time Frame
- From baseline up to approximately 42 months
- measure
- Maximum Serum Concentration (Cmax) of Atezolizumab
- time Frame
- Predose (PRD; 0 hours [hr]), 0.5 hr post-infusion (P-I; infusion duration=30-60 minutes) on Day (D) 1 of Cycle (Cy) 1 and 4 (1 Cy=21 days)
- measure
- Minimum Serum Concentration (Cmin) of Atezolizumab
- time Frame
- PRD (0 hr) on D1 of Cy2,3,4,8, 12, 16 (1 Cy=21 days) and every 8 cycles thereafter; at any time during visit at study drug discontinuation visit, at least 90 days (maximum 150 days) after the last dose of study drug (up to approximately 42 months)
- secondary Outcomes
- measure
- Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 Criteria in Participants With Solid Tumors
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- DOR as Determined by the Investigator Using mINRC in Participants With Neuroblastoma
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- DOR as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- DOR as Determined by the Investigator Using RANO Criteria in Participants With ATRT
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- Overall Survival (OS)
- time Frame
- Baseline until death (up to approximately 42 months)
- measure
- Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Immune-Modified RECIST v1.1 for Participants With Other Solid Tumors
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Immune-Related Response Criteria (irRC) for Participants With Neuroblastoma
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using irRC for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- PFS as Determined by the Investigator Using Immune-Modified RECIST v1.1 for Participants With Other Solid Tumors
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- PFS as Determined by the Investigator Using irRC for Participants With Neuroblastoma
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- PFS as Determined by the Investigator Using irRC for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
- measure
- DOR as Determined by the Investigator Using Immune-Modified RECIST v1.1 for Participants With Other Solid Tumors
- time Frame
- Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
Full study description
- brief Summary
- This early phase, multicenter, open-label, single-arm study evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of atezolizumab in pediatric and young adult participants with solid tumors for which prior treatment was proven to be ineffective.
Source references
- references
- citation
- Nabbi A, Danesh A, Espin-Garcia O, Pedersen S, Wellum J, Fu LH, Paulson JN, Geoerger B, Marshall LV, Trippett T, Rossato G, Pugh TJ, Hutchinson KE. Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab. Nat Cancer. 2023 Apr;4(4):502-515. doi: 10.1038/s43018-023-00534-x. Epub 2023 Apr 10.
- pmid
- 37038005
- type
- DERIVED
- citation
- Geoerger B, Zwaan CM, Marshall LV, Michon J, Bourdeaut F, Casanova M, Corradini N, Rossato G, Farid-Kapadia M, Shemesh CS, Hutchinson KE, Donaldson F, Liao M, Caron H, Trippett T. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. Lancet Oncol. 2020 Jan;21(1):134-144. doi: 10.1016/S1470-2045(19)30693-X. Epub 2019 Nov 25.
- pmid
- 31780255
- type
- DERIVED
- citation
- Shemesh CS, Chanu P, Jamsen K, Wada R, Rossato G, Donaldson F, Garg A, Winter H, Ruppel J, Wang X, Bruno R, Jin J, Girish S. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. J Immunother Cancer. 2019 Nov 21;7(1):314. doi: 10.1186/s40425-019-0791-x.
- pmid
- 31753029
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-401f9acd3fb785cab4b1
- requested nct id
- NCT02541604
- primary nct id
- NCT02541604
- source kind
- fda_spl_label
- source record id
- 4b922b35-c401-4189-a8b2-9f9a820878db
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 17512814b8ce4406095e956c6feded66586b0d9f53d66d16fc4f028d6c044120
- payload
- application numbers
- BLA761034
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-401f9acd3fb785cab4b1
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02541604
- occurrences
- context exact
- muscle invasive bladder cancer. The safety and effectiveness of TECENTRIQ were assessed, but not established in a single-arm, multi-center, multi-cohort trial (NCT02541604) in 60 pediatric patients aged 7 months to <17 years with relapsed or progressive solid tumors and lymphomas. No new safety signals were observed in pediatric
- end
- 1516
- exact text
- NCT02541604
- start
- 1505
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/10/pediatric_use/0
- source kind
- fda_spl_label
- source record id
- 4b922b35-c401-4189-a8b2-9f9a820878db
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- ec8838b86df4e9cb23278fdff25f32a2416a1c3b82a357ecbfcb05a7261b8b5a
- spl effective time
- 20260520
- spl set id
- 6fa682c9-a312-4932-9831-f286908660ee
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-e91247d0fe00eb3fffd9
- requested nct id
- NCT02541604
- primary nct id
- NCT02541604
- source kind
- fda_spl_label
- source record id
- 4b922b35-c401-4189-a8b2-9f9a820878db
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 570c4aa834f21e8e66b5354534758ff3712552d05f3c3076266b9318fd93c052
- payload
- application numbers
- BLA761034
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-e91247d0fe00eb3fffd9
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02541604
- occurrences
- context exact
- muscle invasive bladder cancer. The safety and effectiveness of TECENTRIQ were assessed, but not established in a single-arm, multi-center, multi-cohort trial (NCT02541604) in 60 pediatric patients aged 7 months to <17 years with relapsed or progressive solid tumors and lymphomas. No new safety signals were observed in pediatric
- end
- 4453
- exact text
- NCT02541604
- start
- 4442
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/10/use_in_specific_populations/0
- source kind
- fda_spl_label
- source record id
- 4b922b35-c401-4189-a8b2-9f9a820878db
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- d93f2859f32db3ebaa0913eea50181008102501690b7e12ce48b353b2f77ecba
- spl effective time
- 20260520
- spl set id
- 6fa682c9-a312-4932-9831-f286908660ee
Preserved source evidence · Not medical advice